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Biotechnology Process Patents:
Is Special Legislation Needed?*
Timothy P. Linkkila & Timothy E. Tracy**

Introduction
The human genome project is the largest focused U.S. scientific
endeavor since the push to put a human on the moon. Hundreds of
millions of taxpayer dollars fund research at the Department of Energy
and the National Institutes of Health. 1 The ultimate goal is to
develop and deliver diagnoses and treatments for alleviating human
suffering. Initially, research was publicly funded, but, as treatments are
developed, there is an opportunity to shift funding from the public to
the private sector. For this shift to occur, firms in the biotechnology
industry must be able to recoup their research investments and a fair
return (in view of the risks) on those investments.
Due to its relative youth, the field is still highly speculative.
Industry analysts have estimated that the average cost of discovering
and bringing even a conventional drug to market exceeds $359
million. 2 Companies cannot be expected to advance such sums
without some assurances of return. The biotechnology industry is
nevertheless one of the fastest growing in the U.S., with sales of $2.9
billion in 1990 alone.3 While the U.S. currently leads the world in
*
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See, e.g., Robert M. Cook-Deegan, Origins of the Human Genome Project, 5

Risk 109 (1994) (Table 1).
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See, e.g., Nancy A. Nichols, Scientific Management at Merck: An Interview

with CFO Judy Lewent, 72 Harv. Bus. Rev. 89 (1994).
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biotechnology research, Germany and Japan are said to have had
4
greater commercial success.
As discussed in more detail by Dr. Murashige, 5 the two basic
ways for private firms to recover costs and a reasonable return on R&D
investments are trade secrets and patents. Trade secrets are especially
6
useful for processes, but they are sometimes difficult to maintain.
Also, compared with patents, they may interfere with broad
dissemination of information and further research. Unlike owners of
trade secrets, patentees must tell others how to practice claimed
inventions, 7 and, while patents can prevent commercial exploitation
of claimed subject matter for seventeen years, researchers can build on
their disclosures long before. 8 Thus, patents deserve careful attention
from both public and private perspectives.
This paper examines proposed changes to tailor patent law for the
domestic biotechnology industry. First, it examines the problem as seen
by some members of the industry and bills that have already twice
passed the Senate. Then, it reviews major bases for organized
opposition; e.g., some feel that, if there is a problem, the cures are
worse than the disease. Finally, it provides further reasons for believing
that passage of current bills is unwarranted.
Background on the Proposed Legislation
The U.S. patent system provides coverage for a host of inventions,
including living organisms. 9 However, while a new microorganism is
patentable, its value usually derives not from the microorganism itself
4 David Beier & Robert H. Benson, Biotechnology Patent Protection Act, 68
Den,. U. L.Rev. 174 (1991).
5 Kate H. Murashige, Overview of Potential Intellectual Property for
Biotechnology, 5 Risk 119 (1994).
6 Id., e.g., at 131.
7 35U.S.C.§11251.
8 Indeed, research may even be for commercial purposes. See, e.g., 35 U.S.C.
271 (e) - largely designed to overcome the holding in Roche Products, Inc. v. Bolar
Pharmaceutical Co., 733 F.2d 858 (Fed. Cir. 1984).
9 Diamond v. Chakrabarty, 447 U.S. 303 (1980).
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but from something it makes. In understanding the problem that
concerns members of the biotechnology industry, it is important to
distinguish three things: (1) a living entity that may be patentable if it is
new and unobvious to those practicing in the field (PT 1 ), (2) its
product (PT 2 ), and (3) the process whereby PT1 produces PT 2 (PR).
Often, PT 2 is a product such as insulin. If PT 2 and its function are both
known, that product is unpatentable. Thus, R&D costs can be recouped
only with patent claims covering PT 1 or PR.
Moreover, as also mentioned by Dr. Murashige, 10 if someone
holds a U.S. patent on PR, it can be used to prevent others from not
only practicing the process in the U.S. but also importing PT 2 .
However, the Federal Circuit has found that one who holds a patent on
PT 1 , but not on PR, cannot prevent importation of PT 2 .11 Thus,
inventors of PT 1 - type products, to exclude unpatentable end products
made abroad, also need protection for PR.
Yet, another Federal Circuit case, Durden,12 has raised obstacles.
There, the Court held that patentable starting materials (or novel end
products) do not render an otherwise obvious process patentable. While
the Court limited its holding to the specific facts of that case, 1 3 and

the case appears to be inconsistent with an earlier decision more directly
applicable to biotechnology processes, 14 the U.S. Patent and
Trademark Office (PTO) has used Durden regularly to deny claims
on processes. 15 Moreover, the Federal Circuit has been unable to
resolve the apparent inconsistency in its cases. Although two recent
10 Supra note 5 at 127.
11 Amgen, Inc. v. United States Int'l Trade Comm'n, 902 F.2d 1532 (Fed. Cir.
1990) (Amgen filed a complaint with the ITC to prevent importation of an
unpatented product, manufactured in Japan using patented genetically engineered

host cells. The ITC terminated its investigation for lack of subject matter jurisdiction.
The Court vacated and remanded, holding that the ITC should have treated the
complaint on the merits and that the claims of Amgen's patent did not cover a
process for producing the imported product.).
12 In re Durden, 763 F.2d 1406 (Fed. Cir. 1985).
13 763 F.2d, at 1410.
14 In re Mancy, 499 F.2d 1289 (C.C.P.A. 1974) (a standard technique of culturing
microorganisms to produce antibiotics could not be used to render a similar method
obvious when the process used a patentable microbe).

15 See, e.g., Beier & Benson, supra note 4, at 176; see also, S. Rep. No. 82, at 8.
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cases, Pleuddemann16 and Dillon,17 cast doubt on the continuing
vitality of Durden, neither reverses it. Further, the discussion in
18
Dillon was dicta.
Moreover, while Pleuddemann reversed a PTO rejection of process
claims for a known bonding technique using a novel compound, the
Court distinguished Durden on the basis that it concerned a process of
1
making whereas Pleuddemann sought a process of using. 9
Unfortunately, the process of interest for reasons given ,above, involves
both using and making, i.e., PT, uses PR to make PT 2 . Critics
maintain that one cannot predict what examiners, members of the PTO
Board of Patent Interferences and Appeals (BPAI) or the Federal
Circuit will do.
While some two-thirds of PTO process claim rejections based on
Durden can be overcome, 2 0 this requires a showing of "unexpected
results" and often means additional scientific experimentation and
negotiation with the PTO. Not only are the costs of such
experimentation and negotiation particularly disadvantageous to
universities and smaller firms, but the uncertainty is regarded as
21
generally detrimental to the domestic biotechnology industry.
16 In re Pleuddemann, 910 F.2d 823 (Fed. Cir. 1990).
17 In re Dillon, 919 F.2d 688 (Fed. Cir. 1990) (en banc).
18 "Dicta" indicates that the court did not need to address the issue. Process claims
were not before the court, but it stated, 919 F.2d, at 695:
Suffice it to say that we do not regard Durden as authority to
reject as obvious every method claim reading on an old type of
process, such as mixing, reacting, reducing, etc. The materials used
in a claimed process as well as the result obtained therefrom, must
be considered along with the specific nature of the process and the
fact that new or old, obvious or nonobvious, materials are used or
result from the process are only factors to be considered....
[W]hen any applicant properly presents and argues suitable
method claims, they shouldi be examined in light of all these
relevant factors, free from any presumed controlling effect of
Durden. (Emphasis addled)
19 910 F.2d, at 828.
20 Lisa J. Raines, Protecting Biotechnology's Pioneers, Issues in Sci. & Tech.,
Winter 1991-92, at 33, 35.
21 Id.
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Critics unsatisfied with the way that things have been handled in
the courts and agencies, have turned to Congress 22 for specially
crafted relief.23 As summarized by Herbert Wamsley in 1992:24
Rep. Rick Boucher... and Sen. DeConcini are
sponsoring legislation to amend... the patent code to
make it easier to Qbtain claims for certain processes. The
legislation is entitled the "Biotechnology Patent
Protection Act of 1991," but covers all fields.... Section
103... would be amended to provide that if a product
claim in a patent application is patentable, then the
process of making or using the product is also
patentable.
Hearings were held on the Boucher-DeConcini
legislation in both houses... in 1991, and hearings were
held on a predecessor bill in the House in 1990. The
Senate Judiciary Committee filed its report in March
1992. Proponents urge that the legislation is needed to
remedy problems caused by the manner in which the...
PTO... is applying... In re Durden.
In September 1992, the Senate passed an amended version 25 of the
Biotechnology Patent Protection Act of 1991, but the House did not
pass an equivalent bill. 2 6 Reintroduced as the Biotechnology Patent
Protection Act of 1993, S.298 passed by voice vote on July 15, 1993.27

22 See, e.g., 139 Cong. Rec. S8815-06 (daily ed. July 15, 1993). See also,
e.g.,Michael W. Blommer, Washington Letter, AIPLA Bull., Apr.-June 1993, at
429.
23 Special protection for a particular industry is not unheard of; see supra note 8.
Also, in the 19th Century, land grants were provided to railroads or construction
of infrastructure. Such grants have been called patents; see U.S. v. Northern Pac. Ry.
and Northern Pac. Ry. v. U.S., 311 U.S. 317 (1940).

24

Intellectual Property Laws and Bills of the 102d Congress, A Legislative

Overview, 39 Fed. B. News &J. 260 (1992).
25 As amended, new Title II of the bill also added an amendment to 35 U.S.C. §
271 to forbid, e.g., importation of a product made by using a biotechnological

material, hence filling the gap left by the Amgen case discussed supra at note 12.
26
27

Senate Passes Biotechnology BilL J..Proprietary Rts., Nov., 1992, at 22.
139 Cong. Rec. S8815-06 (daily ed. July 15, 1993).
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28
Title I of S.298 primarily provides that:
[35 U.S.C. § 103] is amended...

(3) by adding at the end thereof the following new

subsections:
(c) Notwithstanding any other provision of this
section, a claimed process of making or using a machine,
manufacture, or composition of matter is not obvious
under this section if...
(2) the claimed process is a biotechnological
process as as defined in subsection (d)...
(d) For purposes of this section, the term
"biotechnological process" means any method of
making or using living organisms, or parts thereof, for
the purpose of making or modifying products. Such
term includes recombinant DNA, recombinant RNA,
cell fusion including hybridoma techniques, and other
processes involving site specific manipulation of genetic
material.
Opposition to the Proposal

At several hearings, opposition to the proposed amendment to §
103 has been voiced by the American Intellectual Property Law
Association (AIPLA), Intellectual Property Owners (IPO), the National
Association of Manufacturers (NAM) and others, including members
29
of the biotechnology industry itself.
Such opponents question whether there is a problem warranting any
action. First, they point out that capital for biotechnology R&D is far
from scarce. For example, it seems that 85 biotechnology companies
raised $3.7 billion in stock offerings in 1991 alone. 30 In the same vein,
31
it has been reported that:
28 S.298, § 101, 103d Cong., 1st Sess. (1993). See supra note 26 regarding Tide II.
29 But see, 139 Cong. Rec. S8817-06 (daily ed. July 15, 1993) (statement of
Senator Kennedy):
The act is supported by the academic research community as
well as the pharmaceutical and biotechnology industries. It enjoys
wide bipartisan support. The Bush administration supported the bill,
and President Clinton has indicated his support as well.
30 See, e.g., B. J. Spalding, 37 Biotech Firms Raise $1.3 Billion, 10 Biotechnology
481 (1992).
31 Craig W. Johnson, Recent Developments in Venture Capital Financingfor
Biotechnology Companies, C886 ALI-ABA 1, 5 (Biotechnology: Business, Law and
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Driven largely by Amgen's tremendous success with
EPO, the public stock market for biotech companies
caught fire in 1991 and 1992, providing much needed
liquidity... This liquidity in turn encouraged limited
partners to invest more money.... $2.6 billion was
committed to venture capital funds in 1992, up from $1
billion in 1991. A significant part of this new money was
targeted for biotech investments.
Second, critics maintain that, while pending bills are designed to
protect domestic companies from unfair foreign competition, there is
no evidence of need. 32 They point out, too, that a change in § 103
would benefit domestic and foreign firms equally and that foreign
33
corporations receive more domestic patents than U.S. companies do.
Those who oppose amendments to § 103 also point out that, while
34
Durden may have caused problems,
Pleuddemann and Dillon have established that
Durden is not a basis for the automatic or categorical
rejection of all process claims, especially those
incorporating the use of patentable starting materials,
including biotechnological materials.
Others contend that proper application of Durden by the PTO
would not warrant legislative intervention. 35 Also, the PTO seems
Regulation 1993).
In the same ALI-ABA volume, Bruce Alan Mann, Creative Techniques for
Financing Biotechnology, 25, at 28, also relates:
According to Ernst & Young s Eighth Annual Report on the
Biotechnoloy Industry (1993), during 1992 the net burn rate of
public biotechnology companies excee ed $2.1 billion. Because the
public market for traditional equity or debt offerings by even the
most highly regarded biotechnology companies has been subject to
frequent... extended periods in which financing is virtually
impossible, creative financing has become a necessity. As the...
Re ort (p. 50) observed: ' f all the challenges facing biotech
CE~s,financing is the most constant.... But necessity haslong been
the mother of-invention in biotech financing. This industry's
creativity in financing is second only to its innovation in
technology."
32 See, e.g., Biotechnology Patent Protection Act of 1991: Hearings on H.R. 1417
Before the House. on Intellectual Property of the House Judiciary Comm., 102d
Cong., 1st. Sess. (1991), at 118-120 (statement of Donald S. Chisum) (hereafter H.R.
1417 Hearings).
33 Id.at 121.
34 Blommer, supra nofe 23, at 430.
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willing to cooperate, having already expressed official approval of
pending amendments. 36 Thus, one might expect corrective action.
Moreover, opponents contend that the biotechnology industry
already receives many process patents and that it is poor public policy
for a single industry to receive special treatment without showing
unique problems. 3 7 They believe that giving special protection to
biotechnological processes would "undermine the credibility of our
patent system." 3 8 AIPLA, for example, foresees no end to special
39
interests thereafter insisting on having their day on Capitol Hill.
Even if there is a problem in the biotechnology industry, opponents
also believe that still more serious legal problems could be created by
amending § 103. They argue that making certain classes of claims per
se nonobvious could result in many process patents on otherwise
unpatentable inventions 4 0 and add uncertainty to patent
enforcement. 4 1 In their view, the scope of existing patents could be
eroded, and, without careful examination, new process patents could
remove technology from the public domain. 4 2 Thus, they predict a
flood of litigation to resolve ambiguities should the amendments be
enacted.
Looking beyond U.S. borders, opponents are concerned that
changes would threaten global efforts to harmonize patent laws and
reduce international trade restrictions. 4 3 Indeed, they fear violating
both the North American Free Trade Agreement and the agreement on
35 Telephone interview with Mr. E. Anthony Figg, Chair, ABA-Intellectual Property
Biotechnology Committee (Nov. 8, 1993).
36 S. Rep. No. 82, at 3 (1993). See also, supra note 30.
37 110 Daily Exec. Rep. (BNA) d18 (1993).
38 H.R. 1417 Hearings, at 430 (statement of Donald S. Chisum).
39 Id.
40 H.R. 1417 Hearings, at 102 (statement of Donald S. Chisum).
41 Biotechnology Patent Protection Act of 1990: Hearings on H.R. 3957 and H.R.
5664 Before the House. on Intellectual Property of the House Judiciary Comm.,
101st Cong., 1st. Sess. (1990).
42 H.R. 1417 Hearings, at 172 (statement ofJohn J. Kelly) and at 103 (statement of
Donald S. Chisum).
43 H.R. 1417 Hearings, at 121 (statement of Donald S. Chisum).
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Trade Related Intellectual Property (part of the General Agreement on
Tariffs and Trade). Articles 1709.7 and 27.1 of those respective
agreements each provide that patents must be available if an
invention (is) new, result(s) from an inventive step and
(is) capable of industrial application.., patent rights shall
be available without discrimination as to the field of
technologv. [Emphasis added.]
This raises the possibility that, if biotechnology processes get special
protection, the U.S. would facially breach those agreements. 4 4 Indeed,
AIPLA is concerned that the bill, if passed, could reduce expected
benefits of these agreements to a "few crumbs" because other countries
could respond with legislation making it more difficult for U.S.
45
inventors to receive protection abroad.

Further Thoughts on Special Protection
A few who seek special protection make arguments that are
overblown. They suggest that biotechnology was invented in the U.S.,
but biotechnology has long been used, e.g. to brew beer, ferment wine
and make bread. Indeed, Mendel's famous pea experiments in the early
19th Century can be viewed as the beginnings of modern
46
biotechnology.
Some proponents of pending bills also appear to believe that
biotechnology inventions can be protected only by patents. 4 7 Yet, for
many processes, trade secrets may be preferable. Process patent
infringement is often impossible to detect, making enforcement
44 Blommer, supra note 23 and Michael W. Blommer, Washington Letter, AIPLA
Bull., Jan.-Feb 1994, at 188.
45 Blommer, supra note 23, at 432. However proponents maintain that the bill
violates neither article because all biotechnology processes are treated equally. Id. and
Blommer (1994) supra note 43.
46 See also, Cook-Deegan, supra note 1, e.g., at 110.
47 One commentator suggests that trade secret protection suffers because, to attract
the most skilled scientists, biotechnology companies need to allow their scientists to
publish. She also argues that small biotechnology companies require legally recognized
property such as patents to raise capital. See Sheryl Rubenstein Silverstein, 66 S. Cal.
L Rev. 937 (1993). Still, it is difficult to see how these points effectively counter the
inability to police patents that cover many processes.
5 Risla Health, Safety &Environment 177 [Spring 1994]

difficult at best. That aside, a process finally used commercially may
not be the same as one that led to an earlier patent but may be
unpatentable over it. Also, institutions with limited resources may find
that pursuing more than one patent on essentially the same process is
not cost justified.
If the PTO itself is unable to solve problems involving the
obviousness of process claims, the Federal Circuit should be allowed
further opportunity to deal with them before Congress steps in. Indeed,
although the Senate has acted, the House appears to be giving the
49
48
Court such an opportunity before voting.
Major pharmaceutical companies do not see a serious problem with

the present law. They regard emerging biotechnology as primarily a
potent tool for developing drugs. 5 0 Their current goal is to discover
the active site(s) on biotechnology-produced proteins and to use
rational drug design 5 1 to develop small molecules that mimic the

activity of these proteins at less cost. Although rational drug design has
been somewhat elusive, as technology progresses, drugs and other

biologically active products may commonly be developed this way.
48 Ex parte Ochiai, 24 U.S.P.Q.2d 1265 (BPAI 1992) is now on appeal. It involves
claims directed to a process of making an AB product. The process of introducing A
into AB or reacting A with B are standard processes used by practitioners in the prior
art for reacting similar A moieties with the same B moiety.
In upholding a rejection of process claims, the Board noted at 1268, that:
The chicken/eg conundrum discussed by appellants...
presents a real world gilemma to a patent examiner.... Faced with
the use of a novel and unobvious material to make a novel and
unobvious product, it is difficult to determine whether the invention

is patentable as a "use" of the new starting material or unpatentable
as a "method of making" the final product. Moreover, it is difficult

to divorce from the patentability consideration the novelty and
unobviousness of starting materils and final products when one is
constantly advised to consider the invention as a whole when
reaching ihe ultimate conclusion of patentability.
49 H.R. Rep. No. 433, 103d Cong., 2d Sess. (1994).
50 Interview with Mr. Charles Caruso, Director of International Patents, Merck &
Co., Inc., in Concord, NH (Nov. 8, 1993).
51 Rational drug design is a process that uses protein structures to determine the
active sites for a given protein and uses this data in computer simulation to design
organic molecules that 'fit" the active sites. It is hoped that by designing compounds
in this manner the amount of bench research required to produce an array of similar
compounds will be greatly reduced.
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End products that do not occur naturally 52 also offer important
intellectual property advantages. 53 They are apt to be patentable, and,
because such products are marketed, it is relatively easy to determine
whether patents are being infringed. Moreover, patents on such
products are infringed in any country where they are obtained regardless of how or where they are made. R&D that focuses on such
products generally renders process protection of litde importance.
This brings up Title II of the pending bills, a recent addition that
has received less attention. It provides that, e.g., use or sale of
unpatentable end products made by a patented "biotechnological
material" constitutes infringement regardless of where the patented
starting material is used. Superficially, this change appears trivial insofar
as § 2 71(g) already provides that sale of an unpatented product made
by a patented process, even if done abroad, constitutes infringement.
54
Yet, Title II is said to suffer the same faults as its companion.
For example, because it lacks safeguards that appear in § 2 7 1 (g), Title
II covers any product made by (or by using) a patented living organism.
Thus, unauthorized sale of bread made with a genetically modified
yeast or milk from a transgenic cow could constitute patent
infringement. One prominent patent attorney has asked on behalf of
55
IPO and NAM:
Does the Congress want bread, milk and all other
manner of everyday commodities to come within the
patent laws simply because a patented biotechnical
material was involved in their production?

52 E.g., purified DNA encoding a specific amino acid sequence, a host cell
transformed with DNA encoding a specific amino acid sequence or a protein in
purified and isolated form.
5 Another advantage is that biotechnology-based therapeutics are very expensive to
develop and market compared to synthesized molecules, such as Proscar@.
54 Statement of Robert A. Armitage (prepared for June, 1993 hearings concerning
H.R.760, the equivalent of S.298) - copy provided by IPO.
55 Id. at 14.
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Summary and Conclusion
The health of a thus-far thriving domestic biotechnology industry is
clearly important to the economic well being of the U.S. However,
perceived inadequacies in the patent law are said to present obstacles to
optimum growth and to encourage free riding by firms abroad. This
had led to proposed federal legislation. From our examination of the
bills and arguments on both sides, we agree with opponents that there
are serious flaws in pending proposals.
One proposal would change the law of nonobviousness to reduce
uncertainty, but it could easily create more uncertainty than it resolves.
If such a change is warranted in view of basic objectives of the patent
system, it is difficult to justify its limitation to biotechnology alone.
Attempting to do so may run afoul of new treaty obligations and
generally interfere with global efforts to reduce trade barriers and
harmonize intellectual property law.
This seems likewise true of a second proposal to reduce free riding
by foreign forms. That proposal expands the set of acts that constitute
patent infringement and is superficially similar a 1988 amendment, but
close consideration reveals a serious lack of safeguards. It is not tailored
finely enough and is apt to have serious and unintended domestic
consequences.
Thus, we conclude that, at least without substantial revision, the
pending Biotechnology Patent Protection Act of 1993 will provide
abundant opportunities, even for its proponents within the
biotechnology industry, to win a small battle and lose a big war.

